GH Research (GHRS) FCF Payout Ratio (2023 - 2025)
GH Research (GHRS) posted quarterly FCF Payout Ratio of 0.31 for Q3 2025, up 229.94% year-over-year from 0.09 in Q3 2024, and up 130.89% quarter-over-quarter from 1.0 in Q2 2025.
GH Research (GHRS) FCF Payout Ratio (2023 - 2025) Analysis & Trends
GH Research's FCF Payout Ratio history runs 3 years deep, the most recent figure standing at 0.31 for Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.17 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.07 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 0.31 |
| Jun 30, 2025 | -1.00 |
| Mar 31, 2025 | -28.59 |
| Sep 30, 2024 | -0.24 |
| Jun 30, 2024 | -0.97 |
| Mar 31, 2024 | -8.08 |
| Sep 30, 2023 | 1.01 |
| Jun 30, 2023 | 1.03 |
| Mar 31, 2023 | -15.31 |